If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
=== Organic chemistry === In organic chemistry, menthol is used as a chiral auxiliary in asymmetric synthesis. For example, sulfinate esters made from sulfenyl chlorides and menthol can be used to make enantiomerically pure sulfoxides by reaction with organolithium reagents or Grignard reagents. Menthol reacts with chiral carboxylic acids to give diastereomic menthyl esters, which are useful for chiral resolution.
== Function == Prostacyclin chiefly prevents formation of the platelet plug involved in primary hemostasis (a part of blood clot formation). It does this by inhibiting platelet activation. It is also an effective vasodilator. Prostacyclin's interactions contrast with those of thromboxane (TXA2), another eicosanoid. Both molecules are derived from arachidonic acid, and work together with opposite platelet aggregatory effects. These strongly suggest a mechanism of cardiovascular homeostasis between these two hormones in relation to vascular damage.
Pyruvate:ferredoxin oxidoreductase, which converts pyruvate into acetyl-CoA and CO2 while reducing the ferredoxin. Hydrogenase, which converts H+ into H2 while oxidizing the ferredoxin. Acetyl-CoA synthetase (in reverse), which converts acetyl-CoA and ADP + Pi into acetate, coenzyme A, and ATP. (A variant of the reaction uses acetate:succinate CoA transferase and succinyl-CoA synthatase in reverse.) The net reaction is conversion of singular equivalents of pyruvate, ADP, and Pi into ATP, CO2, acetate, and H2.
== Identification and interpretation == The process of crystal identification involves comparing them to images of crystals in different solvents found in published sources. Although the shape of the crystals depends on the solvent and, to a certain degree, the substance concentration, it is usually possible to recognize the fundamental crystalline forms. Care should be taken to differentiate between undissolved substances, which might be crystalline but lack a characteristic shape, and recrystallized substances. Microcrystal samples cannot be preserved for long, as they start to degrade within hours or days. Distinguishing between gyrophoric acid and lecanoric acid using thin-layer chromatography can be challenging. However, if one of these substances is known to be present, a microcrystal test can help differentiate them. In the GAW solvent system, lecanoric acid forms long, curved crystal clusters, although the results can be inconsistent, especially in the presence of other substances. Gyrophoric acid, when present in the GE solvent system, may manifest as small, fine crystal clusters or rounded aggregations of tiny crystals. Lecanoric acid in the GE solvent system produces needle-like crystal clusters, but these are not as well-formed as in GAW. These tests can help distinguish Punctelia borreri (which contains gyrophoric acid) from Punctelia subrudecta (which contains lecanoric acid). When two substances generate similar-looking crystals, their optical properties can be used to differentiate between them.
Sources: en.wikipedia.org
These analogues were studied for neurodegenerative diseases, demonstrating improved stability and brain penetration, strong binding affinity to the targeted receptors, and positive effects on cognitive function and neuroprotection in animal models. IRAP inhibitors have also been found to counteract acetylcholine-induced vasoconstriction in vivo, highlighting IRAP's role in modulating vascular function. IRAP deletion reduces susceptibility to pentylenetetrazol-induced seizures in mice, suggesting its potential as epilepsy therapeutic target. IRAP plays an important role in the regulation of the immune system. Similarly to ERAP1 and ERAP2, IRAP is able to trim the N-terminal of antigenic peptides, reducing their length to 8-10 amino acids, the optimal length for MHC class I binding. In contrast to ERAP1 and ERAP2, there is no evidence of IRAP-mediated trimming of antigenic peptides in the endoplasmic reticulum for the MHC-I presentation through the direct pathway. On the other hand, IRAP has a primary function in cross-presentation. Here, the aminopeptidase trims cross-presented peptides in a specific endosomal compartment, described in dendritic cells, before their loading on IRAP-associated MHC class I molecules. IRAP stabilizes the particular type of regulated early endosomes it is located in. The stability of these endosomes is essential for the cross-presentation pathway in dendritic cells, and regulates several endosomal signaling pathways (TCR, TLR9, TNFα, IL-6) in other immune cell types.
== Football career == He made his debut in 2001 with the Essendon Football Club and proved to be a solid ruckman for a number of years. In 2006, Hille was appointed stand-in captain after Matthew Lloyd suffered a season-ending hamstring injury in round three. He captained his first game in Round 6, 2006. From 2007 to 2012, he held the role of vice-captain of the Essendon Football Club which he shared with Mark McVeigh for the most part. In the Round 17, 2006 clash between Essendon and Brisbane Lions (the first match Essendon won under his captaincy, and since the beginning of April that year), Brisbane ruckman Jamie Charman fell heavily in a contest, seriously injuring his shoulder. The image of David Hille comforting his opponent whilst medical help arrived was often replayed by the football media as a rare example of sportsmanship in such a competitive game. At the 2008 Essendon Best and Fairest, Hille swept the floor by taking the most prestigious award of the night, the 'Best and Fairest'. Hille also came away with the 'Cheersquad award'. Hille suffered a knee injury in the second minute of the Bombers' annual ANZAC Day match against Collingwood in Round 5, 2009. Scans confirmed he had ruptured his anterior cruciate ligament, requiring a full knee construction and ending his season.
BMS-470539 is a small-molecule experimental drug which acts as a potent and highly selective full agonist of the MC1 receptor. It was discovered in 2003 as part of an effort to understand the role of the MC1 receptor in immunomodulation, and has since been used in scientific research to determine its role in inflammatory processes. The compound was designed with the intention of mimicking the central His-Phe-Arg-Trp pharmacophore of the melanocortins, and this proved to be successful based on its favorable pharmacodynamic profile.
== Function == Mitochondrial aldehyde dehydrogenase belongs to the aldehyde dehydrogenase family of enzymes that catalyze the chemical transformation from acetaldehyde to acetic acid. Aldehyde dehydrogenase is the second enzyme of the major oxidative pathway of alcohol metabolism. Human ALDH2 is especially efficient on acetaldehyde compared to ALDH1.
Super League successfully attracted eight of the ARL clubs. In the 1995 State of Origin series, the ARL forbade the players of those eight clubs from participating in the interstate competition. However, those clubs were allowed to participate in the premiership seasons of 1995 and 1996, while the ARL fought in the courtroom to stop the Super League competition from eventuating. However, Super League conducted a rival competition in 1997. Both the ARL and Super League competitions ran parallel to each other that year. At the close of the season, despite having the financial backing of Optus, the ARL decided that it could not survive if two competitions were run and undertook moves to approach News Corporation and join the national competition that had been created by Super League. As a consequence of the negotiations that followed, the National Rugby League was formed before the 1998 season from the ARL and Super League competitions. From 1998 to 2012, the National Rugby League Partnership, a power-sharing arrangement between News Corporation and the Australian Rugby League (ARL), ran the National Rugby League competition as a consequence of the Super League war. Between the 1998 season and the first few months of the 2012 season the ARL had six out of twelve seats on the NRL Partnership board. In 2012 News Limited exited the partnership on condition that the ARL was restructured with an independent board. The ARL was renamed as the Australian Rugby League Commission and restructured on 10 February 2012 and took control of the National Rugby League competition.
Sources: en.wikipedia.org
The primary use for indigo is as a dye for cotton yarn, mainly used in the production of denim cloth suitable for blue jeans; on average, a pair of blue jeans requires 3–12 grams (0.11–0.42 oz) of dye. Smaller quantities are used in the dyeing of wool and silk. Indigo's widespread use was partly due to its colorfast properties, as it binds effectively to fibers while allowing repeated dyeing processes that produce a range of shades. Indigo carmine, also known as indigo, is an indigo derivative which is also used as a colorant. About 20,000 tonnes are produced annually, again mainly for the production of blue jeans. Indigo is also used to dye the skin in Egypt, Kurdistan, and West Africa.
Catatonia associated with autism spectrum disorder Catatonia associated with schizophrenia spectrum and other psychotic disorders Catatonia associated with brief psychotic disorder Catatonia associated with schizophreniform disorder Catatonia associated with schizoaffective disorder Catatonia associated with a substance-induced psychotic disorder Catatonia associated with bipolar and related disorders Catatonia associated with major depressive disorder Catatonic disorder due to another medical condition If catatonic symptoms are present but do not form the catatonic syndrome, a medication- or substance-induced aetiology should be considered first.
On 8 April 2026, the United States and Iran agreed to a two-week ceasefire in the 2026 Iran war, mediated by Pakistan. Iran had rejected the draft proposal for a 45-day two-phase ceasefire framework introduced on 5 April by Pakistan, instead proposing its own 10-point plan for a peace agreement. The proposal was developed as part of ongoing mediation efforts involving regional and international actors during the 2025–2026 negotiations. Since its declaration, the ceasefire was violated by both sides numerous times. On 21 April, US president Donald Trump extended the ceasefire indefinitely. On 8 July, the ceasefire deal collapsed after attacks by both sides. Low-intensity fighting between the US and Iran continued intermittently. Later, Trump decided to arrive at a more comprehensive ceasefire that would lead to an US–Iranian agreement. As a result, new ceasefire conditions were agreed upon on 12 June. On 17 June, the presidents of both countries signed the Islamabad Memorandum, a memorandum of understanding that formalized the process of ending the war and established a 60-day period to negotiate the final terms of a deal.
=== Books === Boitano, Scott; Brooks, Heddwen L.; Barman, Susan M.; Barrett, Kim E. (2016). Ganong's Review of Medical Physiology. McGraw-Hill Education. ISBN 978-0-07-182510-8. Susan Standring, ed. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Cole, Laurence A.; Kramer, Peter R. (2016). Human Physiology, Biochemistry and Basic Medicine. Amsterdam: Academic Press. ISBN 978-0-12-803699-0.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.